PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amerise Biosciences Ltd (formerly Amradeep Industries Limited) reported its un-audited financial results for Q1 FY26, with revenue from operations of Rs. 6.37 lacs, entirely from other operating income (no product sales). Total expenses stood at Rs. 7.18 lacs, mainly employee costs (Rs. 2.32 lacs) and other expenses (Rs. 4.86 lacs), resulting in a loss before tax of Rs. 0.81 lacs. Net loss for the quarter came in at Rs. 0.81 lacs versus a loss of Rs. 4.87 lacs in Q1 FY25, showing a meaningful narrowing of losses year-on-year. For the full year FY25 (audited), the company posted revenue of Rs. 18.80 lacs and a marginal net profit of Rs. 0.57 lacs. The auditor (BIPIN & Co.) issued an unqualified limited review report, with no qualifications or emphasis of matter. Notably, other equity stands at negative Rs. 122.71 lacs as on 31 March 2025, indicating accumulated losses have eroded shareholders' funds well below the paid-up capital of Rs. 660.69 lacs.
The company remains in a fragile position with negligible revenue and negative reserves, though the sharp reduction in quarterly losses is a positive signal. Shareholders should watch for any revival in core business activity or fundraising, as continued losses against a wiped-out net worth raise long-term solvency concerns.